Join us on December 14 for our Patient-Focused Sessions on Multiple Myeloma, taking place in Charlotte, NC! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Kristie L. Kahl
The Food and Drug Administration approved the first generic for Afinitor, which can provide a safe, effective, lower cost alternative to the brand-name drug it references.
Katie Kosko
A phase 3 clinical trial investigating Fotivda improved chances of preventing disease progression in patients with kidney cancer compared with Nexavar.
Jessica Skarzynski
Here is a list of clinical trials that are currently happening within the cervical cancer space.
Beth Fand Incollingo
At the annual MPN Heroes event, Dr. David Fajgenbaum, who discovered a treatment for his own rare disorder, shared insights on turning hope into action when faced with adversity.
Jessica Skarzynski
Here is a list of clinical trials that are currently happening within the kidney cancer space.
Katie Kosko
From better breast cancer screening options for service members and their families to a Christmas display that’s raising cancer awareness, here’s what is making headlines in the cancer space this week.
Katie Kosko
Two-time cancer survivor Anne Weber feels fortunate to have learned of her BRCA2 gene mutation, as it led to an early diagnosis of aggressive breast cancer.
Tom Castles
New research suggests men with infertility could face a 30% to 60% higher risk of prostate cancer.
 
Tom Castles
A new study suggests the common pill could help prevent deaths from cancer, but it’s not without it's share of side effects. 
 
Jessica Skarzynski
In cancer clinical trials, the goal, or primary endpoint, is often focused on overall survival. However, one expert from the Dana Farber Cancer Institute thinks treatment-free survival should also be documented to provide patients with the data they need to make informed treatment choices.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×